confirmed that YY1-dependent glioblastoma stem cells were sensitive to the CDK9 inhibitors (Alvocidib and Dinaciclib), and the combination of Alvocidib and anti-PD-1 can more significantly reshape the tumor immune microenvironment, enhance the immunotherapy response and inhibit the occurrence of glioma (84). Here, YY1 is linked to central nervous system cancer.